1. New tool to predict severity in Nonketotic Hyperglycinemia, a rare disease

    An international team led by Dr Àngels García Cazorla, a researcher at the Institut de Recerca Sant Joan de Déu and a pediatric neurologist at the SJD Barcelona Children’s Hospital, has presented a new approach to nonketotic hyperglycinemia that can predict the severity in affected children. The study was published in the journal Annals of Neurology.

  2. The size of the corpus callosum could be a possible biomarker for neurodevelopment in fetuses with congenital heart diseases

    Research shows that children with congenital heart defects have a smaller corpus callosum at 32-36 weeks of gestation. BCNatal - Fetal Medicine Research Center, formed by professionals from the Institut de Recerca Sant Joan de Déu (IRSJD) and IDIBAPS, leds this research.

  3. The hidden cells behind B-cell acute lymphoblastic leukemia relapse spotlighted for the first time

    Drs. Susana Rives, Montserrat Torrebadell and Nerea Vega (IRSJD) participate in a study led by Dr. Pablo Menéndez, group leader at the Josep Carreras Leukaemia Research Institut, who has identified a previously noticed population of pre-leukemic cells might be responsible for some relapses in B-cell acute lymphoblastic leukemia (B-ALL).

  4. Describe an epigenetic protein associated with the metastatic process in Ewing's Sarcoma

    A study with Dr. Jaume Mora (IRSJD) team participation and led by the Molecular Pathology of Sarcomas group of the Seville Institute of Biomedicine (IBiS) has described that the G9a protein would be associated with the development of metastases in Ewing's Sarcoma. Therefore, the overexpression of this protein would indicate an adverse prognosis.

  5. EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder

    Dr. Josep Maria Haro (IRSJD) and his research group participating in EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing precision psychiatry by introducing biology into clinical routine.

  6. Institut de Recerca Sant Joan de Déu joins the european platform EBRAIN

    Institut de Recerca Sant Joan de Déu (IRSJD) strengthens its european position in the neuroscience’s field and the human brain’s study with its incorporation to the EBRAINS platform. A digital research infrastructure, created by the Human Brain Project (HBP) and partly funded by the European Union, which brings together a wide range of data and tools for brain research.

  7. Supplementation with dopamine and serotonin precursors could have neuroprotective effects in children with early-onset epilepsy

    A team of researchers at the Institut de Recerca Sant Joan de Déu shows that supplementation with neurotransmitters such as dopamine and serotonin could protect the brains of children under the age of 3 with early-onset epilepsy. The article was published in the scientific journal Developmental Medicine & Child Neurology.

  8. Dementia cases could triple by 2050 if countries do not address the risk factors

    According to a study published in The Lancet Public Health, the number of people with dementia could triple by 2050. This study is conducted by an international research team with the participation of Dr. Ai Koyanagi and Dr. Jacob Louis of Epidemiology of Mental Disorders and Aging from IRSJD.

  9. Researchers discover a key factor that predicts COVID-19 disease severity

    A study led by Drs. Laia Alsina and Iolanda Jordan from the IRSJD evidences a key factor that predicts the severity of COVID-19: an alteration of the first immune response to SARS-CoV-2 infection, in key molecules in the anti-infective response. The study has been published in open access in the journal iScience.